[Adobe Stock]
The PPD CorEvitas Obesity Registry will collect longitudinal data from both clinicians and patients. It will track how therapies are used in practice, how long patients remain on treatment and what safety or tolerability concerns emerge over time. The company says the registry will also capture patient-reported outcomes across a range of care settings.
The registry arrives as real-world persistence data for weight-loss drugs continues to raise questions about how clinical trial efficacy translates outside controlled settings. A Blue Health Intelligence analysis for the Blue Cross Blue Shield Association found that 30% of patients on GLP-1 therapy for weight management stopped within four weeks, before reaching the targeted maintenance dose. Longer-term data from Prime Therapeutics showed only about 8% of patients remained on therapy at three years.
Those drop-off rates highlight a gap that claims data alone struggles to explain. Patients can discontinue because of side effects, cost, insurance barriers, supply shortages or unmet expectations. Claims data, however, rarely shows which factor mattered most.
“Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety and the patient experience associated with obesity care,” said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries, in a press release.
CorEvitas describes its registry model as “regulatory-grade,” emphasizing structured data capture, consistent definitions and auditability designed to support post-authorization safety studies. The company says regulators have accepted the CorEvitas model for long-term postmarket safety work across multiple disease indications. The obesity registry is the fifteenth independent registry in the CorEvitas portfolio; it spans more than 500 investigator sites and longitudinal data on over 100,000 patients.
In recent years, the FDA has increasingly emphasized real-world evidence for postmarket surveillance and some label expansion decisions. The agency has formalized guidance on how RWE can support regulatory submissions. For obesity drugs, where long-term outcomes, cardiovascular effects and durability of weight loss remain active areas of investigation, prospective registries are one path to generate evidence that payers, regulators and prescribers increasingly expect.
More than 100 million U.S. adults live with obesity, according to the CDC, and the global economic impact of obesity is projected to reach $3 trillion annually by 2030, according to WHO.
Filed Under: Metabolic disease/endicrinology
